Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)
24. September 2020 14:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the...
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
23. September 2014 09:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced an out-licensing
agreement for TGR-1202, a novel next generation PI3K-delta
inhibitor. TG...
Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseases
03. September 2014 05:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead
first-in-class inflammation/auto-immune assets, RP6503 and RP3128
in...
Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies
06. Dezember 2013 06:10 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation
of a "first in human" Phase-1 study of RP6530, a...
Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013
19. November 2013 06:35 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for
its clinical lead, RP6530, a novel, dual Phosphoinositide-3...
Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany
09. September 2013 09:04 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster
presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke
University...
Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013
06. September 2013 06:03 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen
Pharmaceuticals S.A. announces a scientific poster presentation on
the...